Author: Lynch Syndrome Ireland

Genetic Counsellors? are they recognised by the HSE???

They are an internationally recognised group of highly skilled healthcare professionals with training and expertise in genomic and genetic medicine and counselling skills.

Their role involves, but is not limited to, interpreting family and medical history to assess whether an inherited genetic condition may be present in a family and whether testing is appropriate. Education about inheritance, genetic testing, screening, and management.

Coming to terms with a genetic illness in the family can leave a person with many questions. What does this mean for me? What does this mean for my child? Will my family be affected?

Genetic counselling is about trying to explain the condition, how it’s inherited and explain any genetic testing results and also to ensure that people as a family understand what is happening.

Genetic counselling is embedded into some hospital departments in Ireland.

Recognition of the profession is also important…are they really recognised by the HSE???? At present, genetic counsellors in Ireland are registered in the UK or at a European level.

The Government needs to step up and fund the genomics/genetics strategy that includes provision for genetic counselling recognition, training and employment of genetic counsellors in the different mainstream models of healthcare.

Genetics is now recognised asa growing and integral part of cancer care, with a role across treatment, early detection and risk reduction.

COLORECTAL Screening in Europe(2019)

The barriers for screening: (have they changed?)

Despite the obvious value of colorectal cancer screening, many barriers exist that must be taken into account when setting up programmes:

• Patient barriers, such as fear, socio-demographic, psychosocial, economic or geographic factors as well as awareness, understanding or lifestyle.

• Health care providers’ barriers, including low screening recommendation, poor coordination and communication between patients and providers, or lack of follow-up.

• Health system barriers, including inadequate access, screening costs, test-specific factors or delays, as well as the capacity to move patients from screening to colonoscopy to effective treatment.

Click to access 466-Document-DiCEWhitePaper2019.pdf

Serendipity Strikes: How Pursuing Novel Hypotheses Shifted the Paradigm Regarding the Genetic Basis of Colorectal Cancer and Changed Cancer Therapy

Discoveries enabled better understanding of how the DNA mismatch repair (MMR) system not only recognises DNA damage but also responds to damage by DNA repair or by triggering apoptosis(cell death) in the injured cell. 

What has happened over the past 37 years was not predictable when this journey began, but it does speak to the power of careful scientific experimentation, following the facts, perseverance in the face of opposition, and the willingness to think outside of established paradigms.

The conclusion that CRCs with MSI responded differently to classical cytotoxic chemotherapy than did non-MSI CRCs and eventually, the key clinical paradigm shift was the discovery of ICT(Immune checkpoint therapy and its unique effect on tumours with MSI.

Some of these concepts required brilliant thinking and interpretation and others seemingly announced themselves after the correct understanding of an unexpected observation. Since this astonishing series of events unfolded over about four decades, there is hope that this remarkable progress will continue into the future.

https://link.springer.com/article/10.1007/s10620-023-08006-z#Sec18

Prospective Lynch Syndrome Database (PLSD)

The Prospective Lynch Syndrome Database (PLSD) is the largest worldwide database on Lynch Syndrome. 
PLSD collates information on carriers of pathogenic or likely pathogenic MMR variants (path_MMR) who are receiving medical follow-up, including colonoscopy surveillance, which aims to achieve early diagnosis and treatment of cancers.

plsd.eu

image caption

The Six Questions Every Cancer Patient Should Ask Before Choosing Treatment

  1. What is the goal of the recommended treatment? Cure, prolong survival, maintain quality of life?
  2. What is my chance of achieving the goal if I do nothing?
  3. How does the recommended treatment improve the chance of reaching the goal?
  4. What are the side effects of the recommended treatment – many are minimal today?
  5. What is the role of clinical trials in the management of my cancer?
  6. If my cancer comes back, what is the goal and how should i best prepare for it now?

Until recently we thought of cancer as being defined by its location in the body – moving forward it will be defined by the cancer’s unique growth driving mutations and biomarkers. In effect, the genetics – biomarker define the cancer rather than the organ where the cancer began.

https://news.cancerconnect.com/treatment-care/the-six-questions-every-cancer-patient-should-ask-before-choosing-treatment?utm_source=CancerConnect&utm_campaign=9bbe0ef80f-EMAIL_CAMPAIGN_9_20_2018_13_9_COPY_02&utm_medium=email&utm_term=0_4403223c9e-9bbe0ef80f-381439095

IS ANYONE LISTENING?

In health care, continuity of care can be defined both in terms of the patient’s experience (i.e., how well the patient feels they were treated) and in clinical quality—how well the sequence of patient services is delivered in the most effective, efficient way, according to clinical best practices, through “integration, coordination and the sharing of information between different providers.”

As patients’ health care needs are now rarely met by a single professional, multidimensional models of continuity have had to be developed to accommodate the possibility of achieving both ideals simultaneously. 

Can we be secure in the knowledge that someone is always listening to us in the healthcare system?

Not only applies to the Emergency Services but also to the medical profession on a successful approach to patient care: the concept of “continuity of care.”

https://www.iaedjournal.org/is-anyone-listening

Camidge and McVeigh Highlight the Role of the Clinical Geneticist Across Cancer Care and Research

Drs Camidge and McVeigh highlight the evolution of the clinical genetics field over time, the process of identifying pathogenic genetic variants, the difficulties of explaining genetic testing results to patients, and more.

https://www.onclive.com/view/camidge-and-mcveigh-highlight-the-role-of-the-clinical-geneticist-across-cancer-care-and-research

Lynch Syndrome? Why it’s important to know about it

Lynch syndrome is caused by an inherited mutation in one of these genes:

People with Lynch syndrome have an increased risk for colorectal, endometrial and other cancers. The cancer risk varies by gene mutation, therefore it is important for people with Lynch syndrome to know which gene mutation they have.

In the past, the risk-management guidelines were the same for people with an inherited mutation in any of the Lynch syndrome genes. As more research has shown different cancer risks for each gene, experts have started to separate the risks and medical options for each individual mutation. Despite these differences, some references discuss Lynch syndrome as though inherited mutations in these genes carry the same risks. 

If you have been told that you have Lynch syndrome, it is important to know which gene has a mutation, so that you can make informed decisions about your medical care. 

In the past, Lynch syndrome was also referred to as “hereditary nonpolyposis colorectal cancer” (HNPCC). This term has fallen out of favour because mutations in these genes also increase the risk for other cancers besides colorectal cancer. 

Embedding formal and experiential public and patient involvement training in a structuredPhD programme: process and impact evaluation

The international evidence shows that PPI is feasible, but evidence on the economic costs of PPI in research is sparse . It shows that drawing on the lived experience of PPI contributors can have positive benefits for health and social care research. It can lead to better outputs , and while it can enhance the quality and relevance of studies the evidence base on its impact remains weak.

There is evidence that PPI in health research can become tokenistic and concern that inviting patients and the public to ‘tinker at the edges’ undermines the broader aim of PPI to democratise research . International evidence shows that researchers are willing to change their practice, but lack of knowledge, skills and experience can hinder their involvement in PPI and they may be apprehensive about using PPI.

Conclusions

Embedding formal and experiential PPI training in a structured PhD programme is a novel approach. The evaluation has identified a number of lessons that can inform future doctoral programmes seeking to embed formal and experiential PPI training.

https://link.springer.com/article/10.1186/s40900-023-00516-4

Not curing cancer but preventing it

Groundbreaking vaccine trials aimed at preventing cancers associated with the genetic disorder Lynch syndrome are currently underway.

Why Lynch syndrome? 

Sanchez explained that patients with Lynch syndrome are born with a genetic defect in a gene that is involved in DNA repair. 

“What happens is that everytime one of our cells is dividing there is new synthesis of DNA and spontaneously in that process there are DNA errors. There are natural systems in our cells that are equipped to recognize that error and correct it so we don’t get mutations all the time,” Sanchez explained. 

“What happens in patients with Lynch syndrome is that the genetic defect they are born with is in one of the genes involved in this process of self repair of DNA errors,” he continued. 

This means that people with Lynch syndrome are more prone than others to replicate these DNA errors over their lifetime which means an increased risk of cancer. 

https://www.fox26houston.com/news/groundbreaking-vaccine-trial-aims-to-prevent-cancers-associated-with-lynch-syndrome?fbclid=IwAR0gWTf-QufrMY70RVmtHxS2DsfiaCnoFO9Sgpndi-ZzdYCu0k85MzG4J0Y